Financhill
Sell
32

GLTO Quote, Financials, Valuation and Earnings

Last price:
$3.22
Seasonality move :
-23.15%
Day range:
$3.12 - $3.33
52-week range:
$2.01 - $16.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.36x
Volume:
11.1K
Avg. volume:
63.2K
1-year change:
-74.98%
Market cap:
$4.4M
Revenue:
--
EPS (TTM):
-$15.54

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GLTO
Galecto
-- -$2.82 -- -51.46% $6.00
ASND
Ascendis Pharma AS
$107.9M -$1.71 296.68% -21.04% $229.05
EVAX
Evaxion AS
$60K -$0.71 -100% -90.33% $13.25
GMAB
Genmab AS
$759.6M $0.23 17.19% 7.82% $29.69
IOBT
IO Biotech
-- -$0.23 -- -3.23% $9.50
NVO
Novo Nordisk AS
$11.9B $0.92 19.3% 36.74% $91.54
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GLTO
Galecto
$3.32 $6.00 $4.4M -- $0.00 0% --
ASND
Ascendis Pharma AS
$177.71 $229.05 $10.8B -- $0.00 0% 26.47x
EVAX
Evaxion AS
$2.40 $13.25 $15.2M -- $0.00 0% 1.59x
GMAB
Genmab AS
$22.86 $29.69 $14.1B 13.59x $0.00 0% 4.79x
IOBT
IO Biotech
$1.32 $9.50 $87M -- $0.00 0% --
NVO
Novo Nordisk AS
$77.02 $91.54 $342.2B 22.81x $1.14 2.16% 7.87x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GLTO
Galecto
-- 1.946 -- --
ASND
Ascendis Pharma AS
128.87% 0.036 9.75% 0.67x
EVAX
Evaxion AS
-- 2.568 -- 2.80x
GMAB
Genmab AS
-- -0.032 -- 5.32x
IOBT
IO Biotech
-- -0.443 -- --
NVO
Novo Nordisk AS
46.15% 1.812 5.59% 0.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GLTO
Galecto
-- -$2.6M -- -- -- -$2.4M
ASND
Ascendis Pharma AS
$87.8M -$106M -59.13% -880.05% -48.32% -$15.8M
EVAX
Evaxion AS
-- -$3.9M -238.97% -- -54.59% --
GMAB
Genmab AS
$673M $188M 22.23% 22.23% 34.83% $257M
IOBT
IO Biotech
-- -$22.6M -- -- -- -$23.1M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B

Galecto vs. Competitors

  • Which has Higher Returns GLTO or ASND?

    Ascendis Pharma AS has a net margin of -- compared to Galecto's net margin of -93.73%. Galecto's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About GLTO or ASND?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 81%. On the other hand Ascendis Pharma AS has an analysts' consensus of $229.05 which suggests that it could grow by 28.89%. Given that Galecto has higher upside potential than Ascendis Pharma AS, analysts believe Galecto is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is GLTO or ASND More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.446%.

  • Which is a Better Dividend Stock GLTO or ASND?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or ASND?

    Galecto quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Galecto's net income of -$2.5M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Galecto's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 26.47x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    ASND
    Ascendis Pharma AS
    26.47x -- $106.2M -$99.6M
  • Which has Higher Returns GLTO or EVAX?

    Evaxion AS has a net margin of -- compared to Galecto's net margin of -64.14%. Galecto's return on equity of -- beat Evaxion AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    EVAX
    Evaxion AS
    -- -$0.50 $74K
  • What do Analysts Say About GLTO or EVAX?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 81%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 452.08%. Given that Evaxion AS has higher upside potential than Galecto, analysts believe Evaxion AS is more attractive than Galecto.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    EVAX
    Evaxion AS
    1 0 0
  • Is GLTO or EVAX More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLTO or EVAX?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or EVAX?

    Galecto quarterly revenues are --, which are smaller than Evaxion AS quarterly revenues of $3M. Galecto's net income of -$2.5M is lower than Evaxion AS's net income of -$1.6M. Notably, Galecto's price-to-earnings ratio is -- while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 1.59x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    EVAX
    Evaxion AS
    1.59x -- $3M -$1.6M
  • Which has Higher Returns GLTO or GMAB?

    Genmab AS has a net margin of -- compared to Galecto's net margin of 27.27%. Galecto's return on equity of -- beat Genmab AS's return on equity of 22.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
  • What do Analysts Say About GLTO or GMAB?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 81%. On the other hand Genmab AS has an analysts' consensus of $29.69 which suggests that it could grow by 29.87%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    GMAB
    Genmab AS
    4 4 0
  • Is GLTO or GMAB More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genmab AS has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.415%.

  • Which is a Better Dividend Stock GLTO or GMAB?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or GMAB?

    Galecto quarterly revenues are --, which are smaller than Genmab AS quarterly revenues of $715M. Galecto's net income of -$2.5M is lower than Genmab AS's net income of $195M. Notably, Galecto's price-to-earnings ratio is -- while Genmab AS's PE ratio is 13.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 4.79x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    GMAB
    Genmab AS
    4.79x 13.59x $715M $195M
  • Which has Higher Returns GLTO or IOBT?

    IO Biotech has a net margin of -- compared to Galecto's net margin of --. Galecto's return on equity of -- beat IO Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    IOBT
    IO Biotech
    -- -$0.34 --
  • What do Analysts Say About GLTO or IOBT?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 81%. On the other hand IO Biotech has an analysts' consensus of $9.50 which suggests that it could grow by 619.7%. Given that IO Biotech has higher upside potential than Galecto, analysts believe IO Biotech is more attractive than Galecto.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    IOBT
    IO Biotech
    2 0 0
  • Is GLTO or IOBT More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLTO or IOBT?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or IOBT?

    Galecto quarterly revenues are --, which are smaller than IO Biotech quarterly revenues of --. Galecto's net income of -$2.5M is higher than IO Biotech's net income of -$22.4M. Notably, Galecto's price-to-earnings ratio is -- while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    IOBT
    IO Biotech
    -- -- -- -$22.4M
  • Which has Higher Returns GLTO or NVO?

    Novo Nordisk AS has a net margin of -- compared to Galecto's net margin of 37.18%. Galecto's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About GLTO or NVO?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 81%. On the other hand Novo Nordisk AS has an analysts' consensus of $91.54 which suggests that it could grow by 18.79%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    NVO
    Novo Nordisk AS
    4 5 1
  • Is GLTO or NVO More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.759%.

  • Which is a Better Dividend Stock GLTO or NVO?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.16% to investors and pays a quarterly dividend of $1.14 per share. Galecto pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLTO or NVO?

    Galecto quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Galecto's net income of -$2.5M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Galecto's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 22.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 7.87x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    NVO
    Novo Nordisk AS
    7.87x 22.81x $11B $4.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 41x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Sell
37
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
49
RGC alert for Jun 17

Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.

Buy
75
ARQQ alert for Jun 17

Arqit Quantum [ARQQ] is up 6.36% over the past day.

Buy
59
SYM alert for Jun 17

Symbotic [SYM] is down 3.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock